Pear Therapeutics (NASDAQ:PEAR – Get Rating) is one of 33 public companies in the “Health services” industry, but how does it contrast to its competitors? We will compare Pear Therapeutics to related businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.
This table compares Pear Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pear Therapeutics Competitors||-325.87%||-481.74%||-38.64%|
This is a summary of current ratings and price targets for Pear Therapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pear Therapeutics Competitors||7||128||274||0||2.65|
Institutional and Insider Ownership
55.4% of Pear Therapeutics shares are held by institutional investors. Comparatively, 47.2% of shares of all “Health services” companies are held by institutional investors. 30.7% of Pear Therapeutics shares are held by insiders. Comparatively, 22.1% of shares of all “Health services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Pear Therapeutics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pear Therapeutics||$4.21 million||-$65.14 million||-8.55|
|Pear Therapeutics Competitors||$1.36 billion||-$98.47 million||28.41|
Pear Therapeutics’ competitors have higher revenue, but lower earnings than Pear Therapeutics. Pear Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Pear Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Pear Therapeutics’ competitors have a beta of 1.48, indicating that their average stock price is 48% more volatile than the S&P 500.
Pear Therapeutics beats its competitors on 8 of the 12 factors compared.
About Pear Therapeutics
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.